Perbak Capital Partners’s ResMed RMD Stock Holding History

Perbak Capital Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$929K	Buy	4,140 +2,738	+195%	+$682K	0.23%	83
2025 Q4	$338K	Sell	1,402 -1,970	-58%	-$504K	0.1%	123
2025 Q3	$923K	Buy	3,372 +1,458	+76%	+$398K	0.16%	143
2025 Q2	$494K	Buy	+1,914	New	+$457K	0.11%	185
2024 Q3	–	Sell	-2,100	Closed	-$402K	–	52
2024 Q2	$402K	Buy	+2,100	New	+$426K	0.12%	55

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Perbak Capital Partners's RMD Position: Q1 2026 in Review

Perbak Capital Partners increased its ResMed (RMD) stake by 195% in Q1 2026, buying an estimated $682K and bringing the position to 4,140 shares worth $929K. The position accounts for 0.23% of the portfolio, ranked #83.

Perbak Capital Partners first reported a position in RMD in Q2 2024 and has held it in 5 quarters since. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Perbak Capital Partners held 4,140 shares of ResMed worth $929K as of Q1 2026.
Perbak Capital Partners bought 2,738 ResMed shares in Q1 2026, an estimated $682K.
ResMed made up 0.23% of Perbak Capital Partners's portfolio in Q1 2026, its #83 holding.
Perbak Capital Partners first reported a position in ResMed in Q2 2024 and has held it in 5 quarters since.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.